XML 46 R29.htm IDEA: XBRL DOCUMENT
v3.22.2.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 27, 2020 | Aug. 31, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | $ 4,522 |  |  | $ 4,522 |  |  | $ 6,013
Novartis Institutes for BioMedical Research, Inc. |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |
Contract asset |  | $ 1,500 |  |  |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |
Proceeds from collaborators |  | $ 75,000 |  |  |  |  |  |  |
Collaborative arrangement transaction price | $ 95,100 |  |  |  |  |  |  |  |
License fee | 75,000 |  |  |  |  |  |  |  |
Collaborative arrangement estimated reimbursable service costs | 20,100 |  |  |  |  |  |  |  |
Accounts receivable |  |  | 2,000 |  |  | 2,000 |  |  | 1,900
Deferred revenue |  |  | 17,700 |  |  | 17,700 |  |  | $ 40,900
Financial advisory fees |  |  |  |  | $ 1,500 |  |  |  |
Percent of initial recognition |  |  |  |  |  |  |  | 2.00% |
Amortization |  |  | $ 200 | $ 200 |  | $ 500 | $ 500 |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | 420,000 |  |  |  |  |  |  |  |
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Commercial Milestones |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | $ 300,000 |  |  |  |  |  |  |  |

X
- Definition Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value + References No definition available. + Details
Name: | sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Percent Of Initial Recognition + References No definition available. + Details
Name: | sgmo_CollaborativeAgreementPercentOfInitialRecognition
Namespace Prefix: | sgmo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement estimated reimbursable service costs. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, License Fee + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementLicenseFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSoldAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |